文献速递主动脉疾病

内分支腔内修复治疗EVAR后Ia型内漏的多中心经验

A Multicentre Experience of Inner-Branched Endovascular Aneurysm Repair for Treatment of Type Ia Endoleak After EVAR.
PubMed 文献 · J Endovasc Ther · 2026-08-24

该多中心回顾性研究纳入20例既往腹主动脉EVAR后发生Ia型内漏、接受择期内分支腔内修复(iBEVAR)的患者,技术成功率为95%,30天临床成功率为80%。中位随访12.0个月期间,30.0%患者因主动脉相关原因再干预,靶血管一期通畅率为96.2%。结论认为该技术可行但脆弱患者群体并发症率高。

要点

  • iBEVAR治疗EVAR后Ia型内漏技术成功率达95%。
  • 30天临床成功率为80%,中位随访12.0个月再干预率30.0%。
  • 随访期靶血管一期通畅率为96.2%。

核心结论

  • 使用iBEVAR近端延伸治疗既往腹主动脉EVAR后Ia型内漏技术上可行。
  • 该技术在脆弱患者群体中伴随较高并发症率。
  • 短期分析显示良好的技术成功率和较高的靶血管通畅率。

研究设计与样本

  • 多中心回顾性研究,连续纳入择期使用iBEVAR修复既往腹主动脉EVAR后Ia型内漏的患者。
  • 共纳入20例患者,其中男性17例,平均年龄75.2岁(SD 1.7岁)。
  • 初次EVAR至iBEVAR的平均时间为6.75年(SD 0.9年)。
  • 主要结局为技术成功,次要结局为30天临床成功。

主要发现

  • 技术成功率为95%,1例患者因术中出血死亡。
  • 30天临床成功率为80%。
  • 中位随访12.0个月(IQR 1.75-25.0)期间,6例(30.0%)因主动脉相关原因再干预。
  • 再干预的中位总体时间为11.0个月(IQR 4.5-11.5)。
  • 随访期间靶血管一期通畅率为96.2%。

关键数值与推荐

  • 技术成功定义为95%病例完成,1例术中出血死亡。
  • 30天临床成功定义为80%病例达成。

临床怎么用

  • 对于既往腹主动脉EVAR后发生Ia型内漏的患者,可考虑使用iBEVAR进行近端延伸修复。
  • 需注意该技术在高危脆弱患者中并发症率较高,应谨慎选择患者。

局限性

  • 样本量小(20例),随访时间短(中位12.0个月)。
  • 回顾性多中心设计。
  • 作者指出未来需关注长期结局和仔细的患者选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the outcomes of inner-branched endovascular aneurysm repair (iBEVAR) for the treatment of type Ia endoleak after infrarenal endovascular aneurysm repair (EVAR). MATERIALS AND METHODS: This multicentre study retrospectively analyzed all consecutive patients who underwent elective revision using iBEVAR for type Ia endoleak after previous infrarenal EVAR. The primary outcome was technical success, and the secondary outcome was clinical success at 30 days. Outcomes during further follow-up were mortality from aneurysm-related causes, type I and III endoleaks, target vessel instability, and aneurysm- or graft-related reinterventions. RESULTS: A total of 20 patients were included in the study; 17 patients were male, and the mean age was 75.2 years (SD 1.7 years). The mean time between initial EVAR and iBEVAR was 6.75 years (SD 0.9 years). Technical success was noted in 95% of cases, as 1 patient died from bleeding sustained during the procedure. Clinical success at 30 days was achieved in 80% of cases. During a median follow-up of 12.0 months (interquartile range [IQR] 1.75-25.0), 6 (30.0%) reinterventions were performed for aortic-related causes. Overall median time to reintervention was 11.0 months (IQR 4.5-11.5). Primary target vessel patency during follow-up was 96.2%. CONCLUSION: Treatment of type Ia endoleak after previous infrarenal EVAR using proximal extension with iBEVAR is technically feasible, yet associated with high morbidity in a fragile patient population. The technique has demonstrated good technical success and high target vessel patency in this short-term analysis. Future research should focus on long-term outcomes and careful patient selection.Clinical ImpactType Ia endoleak is clinically challenging, as treatment using open conversion is associated with high morbidity and mortality. Endovascular methods have been proposed, however often have limitations in applicability and effectiveness. The new iBEVAR cuff has been demonstrated to be effective and applicable in a wide range of anatomical characteristics. The treatment is safe and allows a larger patient population with type Ia endoleak to be treated.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Oosterveld RJ, Hoksbergen AWJ, van Wely C, et al. A Multicentre Experience of Inner-Branched Endovascular Aneurysm Repair for Treatment of Type Ia Endoleak After EVAR. J Endovasc Ther. 2026. PMID: 42635007. doi:10.1177/15266028261479539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。